These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 19936577)

  • 21. Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism.
    Beyer-Westendorf J; Ageno W
    Thromb Haemost; 2015 Feb; 113(2):231-46. PubMed ID: 25319150
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reversal of Anticoagulation and Management of Bleeding in Patients on Anticoagulants.
    Dhakal P; Rayamajhi S; Verma V; Gundabolu K; Bhatt VR
    Clin Appl Thromb Hemost; 2017 Jul; 23(5):410-415. PubMed ID: 27789605
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Andexanet alfa: the best antidote for factor Xa inhibitors?].
    Klok FA; Huisman MV
    Ned Tijdschr Geneeskd; 2019 Jun; 163():. PubMed ID: 31283119
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants.
    Enriquez A; Lip GY; Baranchuk A
    Europace; 2016 Jul; 18(7):955-64. PubMed ID: 25816811
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Management of hemorrhage in patients treated with direct oral anticoagulants].
    Grottke O; Lier H; Hofer S
    Anaesthesist; 2017 Sep; 66(9):679-689. PubMed ID: 28455651
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Treatment with inhibitors of new oral direct anticoagulants in patients with severe bleedings or urgent surgical procedures. The new dabigatran antidote: the place of idarucizumab in clinical practice].
    Boda Z
    Orv Hetil; 2016 Mar; 157(12):443-50. PubMed ID: 26971644
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [New oral anticoagulants (NOAC) in stroke treatment].
    Küpper C; Kellert L; Tiedt S; Wollenweber FA
    Fortschr Neurol Psychiatr; 2018 Feb; 86(2):117-124. PubMed ID: 29117605
    [TBL] [Abstract][Full Text] [Related]  

  • 28. How to effectively manage the event of bleeding complications when using anticoagulants.
    Sartori MT; Prandoni P
    Expert Rev Hematol; 2016 Jan; 9(1):37-50. PubMed ID: 26573697
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New anticoagulants: from bench to bedside.
    Haas S; Schellong S
    Hamostaseologie; 2007 Feb; 27(1):41-7. PubMed ID: 17279275
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of hemorrhagic events in patients receiving anticoagulant therapy.
    Love DG
    J Thromb Thrombolysis; 1999 Apr; 7(2):149-52. PubMed ID: 10364766
    [No Abstract]   [Full Text] [Related]  

  • 31. [Bleeding risk and perioperative management of patients anticoagulated with vitamin K antagnosists].
    Angelo M; Stockner I; Wiedermann CJ
    Wien Med Wochenschr; 2008; 158(21-22):615-20. PubMed ID: 19052707
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reversing anticoagulants both old and new.
    Warkentin TE; Crowther MA
    Can J Anaesth; 2002; 49(6):S11-25. PubMed ID: 12557411
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Established anticoagulants in secondary haemostasis--Vitamin K antagonists, heparins].
    Langer E; Ziemer S
    Hamostaseologie; 2009 Aug; 29(3):241-6. PubMed ID: 19644603
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Major bleeding with old and novel oral anticoagulants: How to manage it. Focus on general measures.
    Di Fusco SA; Lucà F; Benvenuto M; Iorio A; Fiscella D; D'Ascenzo F; Madeo A; Colivicchi F; Di Lenarda A; Gulizia MM
    Int J Cardiol; 2018 Oct; 268():80-84. PubMed ID: 29853278
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Major bleeding with old and novel oral anticoagulants: How to manage it. Focus on reversal agents.
    Di Fusco SA; Lucà F; Benvenuto M; Iorio A; Fiscella D; D'Ascenzo F; Madeo A; Colivicchi F; Di Lenarda A; Gulizia MM
    Int J Cardiol; 2018 Oct; 268():75-79. PubMed ID: 29843897
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reversal Strategies for NOACs: State of Development, Possible Clinical Applications and Future Perspectives.
    Husted S; Verheugt FW; Comuth WJ
    Drug Saf; 2016 Jan; 39(1):5-13. PubMed ID: 26519420
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reversing anticoagulant therapy.
    Ghanny S; Warkentin TE; Crowther MA
    Curr Drug Discov Technol; 2012 Jun; 9(2):143-9. PubMed ID: 22023256
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of a recombinant antithrombin variant as a potent antidote to fondaparinux and other heparin derivatives.
    Bianchini EP; Fazavana J; Picard V; Borgel D
    Blood; 2011 Feb; 117(6):2054-60. PubMed ID: 21048158
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Non-vitamin K dependent oral anticoagulants : What is important in intensive care medicine].
    Gulba DC; Broscaru L
    Med Klin Intensivmed Notfmed; 2017 Mar; 112(2):83-91. PubMed ID: 28144727
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Management of bleeding in patients on antithrombotic therapy].
    Braun G
    Med Klin Intensivmed Notfmed; 2021 Sep; 116(6):491-498. PubMed ID: 34463792
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.